HTA
BIIB icon

Haber Trilix Advisors’s Biogen BIIB Stock Holding History

Haber Trilix Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q2 		$62K Buy
+290
New +$62K 0.01% 221

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Haber Trilix Advisors's BIIB Position: Q2 2013 in Review

Haber Trilix Advisors opened a new position in Biogen (BIIB) in Q2 2013: 290 shares worth $62K. The stake represents 0.01% of the portfolio and ranks #221 among its holdings.

646 funds tracked by Wall St. Rank hold BIIB as of Q2 2013.

  • Haber Trilix Advisors held 290 shares of Biogen worth $62K as of Q2 2013.
  • Biogen was a new Haber Trilix Advisors position in Q2 2013.
  • Biogen made up 0.01% of Haber Trilix Advisors's portfolio in Q2 2013, its #221 holding.
  • 646 funds tracked by Wall St. Rank held Biogen as of Q2 2013.

Based on Haber Trilix Advisors's 13F filing for Q2 2013, filed 14 Aug 2013.